logo
Wary of sticker shock, retailers clash with brands on price hikes

Wary of sticker shock, retailers clash with brands on price hikes

Time of India5 days ago
Caught between rising costs from tariffs and belt-tightening consumers, big retailers are clashing with the producers of consumer brands such as Nivea-maker
Beiersdorf
and brewer Heineken, as they look to avoid sticker shock that could hurt sales.
The disputes - which have dented some brands' sales - underscore the challenge for consumer goods makers and sellers, with
inflation and tariffs
pushing up input costs and price spikes in commodities such as coffee.
While pricing talks have never been easy, tariffs are escalating already high food inflation since the pandemic, making grocery bills more contentious and political as consumers grapple with a cost-of-living crisis.
"We all should be very well aware of consumer budgets," Frans Muller, CEO of supermarket company
Ahold Delhaize
, which owns U.S. chains Food Lion, Hannaford, and Stop & Shop, told Reuters on Wednesday.
He said conversations with consumer goods companies over pricing were "tight," adding that the industry's focus was on increasing sales volumes rather than increasing revenue by hiking prices.
"That is the wrong way of supporting customers and the wrong way of growing the business itself."
Ahold has in-house teams that track commodity, energy, and labour costs, and
own-brand products
it can compare with to establish whether price increases demanded by consumer brands are justified or not, Muller said.
On the other side of the equation are the brands, facing higher costs that are squeezing margins.
Beiersdorf CEO Vincent Warnery said on Wednesday that retailers in key markets, including Germany and France, had pushed back strongly in price talks last quarter, not only refusing price increases but asking for price reductions, and pulling products from shelves.
Beiersdorf eventually agreed to a 2.6% rise, Warnery said, but delistings of some products by retailers knocked two percentage points off its sales growth in Europe in the second quarter.
"There will be a lot of price changes pushed forward by consumer brands, some will be accepted by retailers and some will not," said Bobby Gibbs, a Dallas-based partner at Oliver Wyman who advises retailers and consumer goods firms.
Manufacturers will find it easier to push higher prices through on products where there is brand loyalty and fewer strong private label alternatives, Gibbs said.
Reuters' global tariff tracker shows at least 102 out of nearly 300 companies monitored by the tracker have announced price hikes in response to the trade war, with about 41 of them in the consumer sector.
As well as tariffs, other factors like the cost of capital and labour, and commodity prices in the case of coffee and chocolate, are pushing prices up on certain products, Gibbs said.
Trump has said the tariffs counter persistent U.S. trade imbalances and declining U.S. manufacturing power, and that the moves will bring jobs and investment to the nation.
MORE PRICE HIKES AHEAD
More price hikes are planned, particularly in the U.S.
Tide detergent maker Procter & Gamble last week said it was raising prices on about a quarter of its products in the U.S. by a mid-single-digit percentage as part of efforts to mitigate the cost of higher tariffs on imported goods. That will affect pricing at Walmart, Target, and other stores.
As talks heat up, more retailers could pull branded products temporarily as a negotiating tactic, as Ahold's Albert Heijn chain did this year in a dispute over price hikes by coffee roaster JDE Peet's.
Dutch brewer Heineken last week said its beer sales were dented by a price dispute with European retailers.
"Many retailers are getting more sophisticated in how they can measure product switching ... so they're willing to be bolder on delistings because they're able to protect sales and margin more than they would have in the past," said Gibbs.
In Europe, retailers are joining forces to increase their clout in pricing talks. Carrefour said last month it had created a new European buying alliance called Concordis, along with rival group Cooperative U, and is in advanced discussions with other European retailers to expand the alliance.
Supermarkets are developing more own-brand alternatives to big-name brands. Ahold has introduced 300 new own-brand products this year in its U.S. chains, and sales growth in those has outpaced the rest of the store, it said.
Big brands have taken note, with P&G's Chief Financial Officer Andre Schulten saying last week that retailers have been implementing "more aggressive pricing" on own-brand products.
"We see some level of pressure to drive trade down because of price promotional behaviour," he said, referring to consumers swapping to lower-priced products, adding the market would remain "volatile and challenging".
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million

Economic Times

time14 minutes ago

  • Economic Times

Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million

Synopsis Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy. Agencies Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections. Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.'This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,' said Binesh Chudgar, Intas Pharma's chairman and managing Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA. With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.'The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,' said Chrys Kokino, President, USA, Accord BioPharma.

Upcoming IPO: Fractal Analytics files DRHP with Sebi to raise  ₹4,900 crore via public issue. Details here
Upcoming IPO: Fractal Analytics files DRHP with Sebi to raise  ₹4,900 crore via public issue. Details here

Mint

time16 minutes ago

  • Mint

Upcoming IPO: Fractal Analytics files DRHP with Sebi to raise ₹4,900 crore via public issue. Details here

Upcoming IPO: Mumbai-based analytics firm Fractal Analytics has filed its draft papers with the markets regulator, the Securities and Exchange Board of India (Sebi), on Tuesday, August 12, 2025, to raise funds via an initial public offering. Fractal Analytics was founded by Srikanth Velamakanni and Pranay Agrawal in 2000. The company provides data-driven insights and assists in decision-making through end-to-end AI solutions to large global enterprises across multiple industries. Its major clients include global tech giants such as Microsoft, Apple, Nvidia, Alphabet, Amazon, Meta and Tesla. Fractal Analytics' initial public offering comprises a fresh issue of equity shares worth ₹ 1,279.3 crore and an offer to sale (OFS) equity shares up to 3,620.7 crore. The OFS comprises equity shares worth up to ₹ 1,462.6 crore by Quinag Bidco Ltd, ₹ 1,999.6 crore by TPG Fett Holdings Pte. Ltd, ₹ 29.5 crore by Satya Kumari Remala and Rao Venkateswara Remala; and equity shares ₹ 129 crore by GLM Family Trust. The company is seeking to raise nearly ₹ 4,900 crore from the stock market by issuing equity shares with a face value of Re 1 apiece. The Offer is conducted via the book building process, allocating 75% of the shares to QIBs, 15% to Non-Institutional Investors, and 10% to Retail Individual Investors. Additionally, it includes a reservation not exceeding 5% of the Company's post-offer paid-up equity share capital for eligible employees. Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, Axis Capital Limited, and Goldman Sachs (India) Securities Private Limited are the book-running lead managers for the IPO. Fractal Analytics plans to use the net proceeds from the public issue to invest in its subsidiary, Fractal USA. This investment will cover costs incurred to purchase laptops, establish new office space in India, fund research and development, and support sales and marketing activities under Fractal Alpha. Additionally, the funds will be used to finance inorganic growth through potential acquisitions and other strategic initiatives, as well as general corporate expenses. Fractal's revenue from operations increased by 25.9% to ₹ 2,765 crore in FY25, compared to ₹ 2,196 crore in FY24. Similarly, profit after tax (PAT) turned positive to ₹ 22 crore in FY25 from a loss of ₹ 5.47 crore in FY24. PAT and EBITDA margins also improved to 12.6% from (0.2%) and 17.4% from 10.6%, respectively. Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Terraform Labs founder Do Kwon pleads guilty to US fraud charges in $40 billion crypto collapse
Terraform Labs founder Do Kwon pleads guilty to US fraud charges in $40 billion crypto collapse

Economic Times

time18 minutes ago

  • Economic Times

Terraform Labs founder Do Kwon pleads guilty to US fraud charges in $40 billion crypto collapse

Reuters Do Kwon, a South Korean cryptocurrency executive charged with fraud, stands with his attorney David Patton to plead guilty in front of U.S. District Judge Paul Engelmayer in New York City, New York, U.S., August 12, 2025 in this courtroom sketch. REUTERS/Jane Rosenberg Do Kwon, the South Korean cryptocurrency entrepreneur behind two digital currencies that lost an estimated $40 billion in 2022, pleaded guilty on Tuesday to two US charges of conspiracy to defraud and wire fraud. Kwon, 33, who co-founded Singapore-based Terraform Labs and developed the TerraUSD and Luna currencies, entered the plea at a court hearing in New York before US District Judge Paul Engelmayer. He had pleaded not guilty in January to a nine-count indictment charging him with securities fraud, wire fraud, commodities fraud and money laundering conspiracy. Accused of misleading investors in 2021 about TerraUSD - a so-called stablecoin designed to maintain a value of $1 - Kwon pleaded guilty to the two counts under an agreement with the Manhattan US Attorney's office, which brought the charges. "Do Kwon used the technological promise and investment euphoria around cryptocurrency to commit one of the largest frauds in history," Manhattan US Attorney Jay Clayton said in a statement. He faces up to 25 years in prison when Engelmayer sentences him on December 11, though prosecutor Kimberly Ravener said the government had agreed to advocate for a prison term of no more than 12 years provided he accepts responsibility for his crimes. Kwon is one of several cryptocurrency moguls to face federal charges after a slump in digital token prices in 2022 prompted the collapse of a number of companies. Prosecutors alleged that when TerraUSD slipped below its $1 peg in May 2021, he told investors a computer algorithm known as "Terra Protocol" had restored the coin's value. Instead, they said, he arranged for a high-frequency trading firm to secretly buy millions of dollars of the token to artificially prop up its price. Prosecutors said that false claim and others drove retail and institutional investors to buy Terraform products and boost the value of Luna - a more traditional token that fluctuated in value but was closely linked to TerraUSD - to $50 billion by the spring of 2022. In court, Kwon apologised for his conduct. "I made false and misleading statements about why it regained its peg by failing to disclose a trading firm's role in restoring that peg," Kwon said. "What I did was wrong." Kwon agreed in 2024 to pay $80 million as a civil fine and be banned from crypto transactions as part of a $4.55 billion settlement he and Terraform reached with the US Securities and Exchange Commission. Kwon has been detained since his extradition from Montenegro late last year. He also faces charges in South Korea. As part of the deal, prosecutors will not oppose Kwon's potential application to be transferred abroad after serving half his US sentence, Ravener said. Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Regulatory gray area makes investing in LVMH, BP tough For Indian retail How IDBI banker landed plush Delhi properties in Amtek's INR33k crore skimming As 50% US tariff looms, 6 key steps that can safeguard Indian economy Jane Street blow pushes Indian quants to ancient Greek idea to thrive Stock Radar: Astra Microwave showing signs of bottoming out after 16% fall from highs; time to buy? F&O Radar | Deploy Broken Wing in Paytm to play stock's bullish outlook These 9 banking stocks can give more than 28% returns in 1 year, according to analysts Why 2025 Could Be The Astrological Turning Point We've Been Waiting For

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store